Apoptotic cell–induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans

  • Nature Immunologyvolume 19pages571582 (2018)
  • doi:10.1038/s41590-018-0107-1
  • Download Citation



The transcription factor AhR modulates immunity at multiple levels. Here we report that phagocytes exposed to apoptotic cells exhibited rapid activation of AhR, which drove production of the cytokine IL-10. Activation of AhR was dependent on interactions between apoptotic-cell DNA and the pattern-recognition receptor TLR9 that was required for the prevention of immune responses to DNA and histones in vivo. Moreover, disease progression in mouse systemic lupus erythematosus (SLE) correlated with strength of the AhR signal, and the disease course could be altered by modulation of AhR activity. Deletion of AhR in the myeloid lineage caused systemic autoimmunity in mice, and an enhanced AhR transcriptional signature correlated with disease in patients with SLE. Thus, AhR activity induced by apoptotic cell phagocytes maintains peripheral tolerance.

  • Subscribe to Nature Immunology for full access:



Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Ravishankar, B. et al. Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase. Proc. Natl Acad. Sci. USA 109, 3909–3914 (2012).

  2. 2.

    Ravishankar, B. et al. The amino acid sensor GCN2 inhibits inflammatory responses to apoptotic cells promoting tolerance and suppressing systemic autoimmunity. Proc. Natl Acad. Sci. USA 112, 10774–10779 (2015).

  3. 3.

    Ravishankar, B. et al. Marginal zone CD169+ macrophages coordinate apoptotic cell-driven cellular recruitment and tolerance. Proc. Natl Acad. Sci. USA 111, 4215–4220 (2014).

  4. 4.

    Poon, I. K., Lucas, C. D., Rossi, A. G. & Ravichandran, K. S. Apoptotic cell clearance: basic biology and therapeutic potential. Nat. Rev. Immunol. 14, 166–180 (2014).

  5. 5.

    McGaha, T. L. & Karlsson, M. C. Apoptotic cell responses in the splenic marginal zone: a paradigm for immunologic reactions to apoptotic antigens with implications for autoimmunity. Immunol. Rev. 269, 26–43 (2016).

  6. 6.

    Scott, R. S. et al. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 411, 207–211 (2001).

  7. 7.

    Hanayama, R. et al. Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science 304, 1147–1150 (2004).

  8. 8.

    Hankinson, O. The aryl hydrocarbon receptor complex. Annu. Rev. Pharmacol. Toxicol. 35, 307–340 (1995).

  9. 9.

    Stockinger, B., Di Meglio, P., Gialitakis, M. & Duarte, J. H. The aryl hydrocarbon receptor: multitasking in the immune system. Annu. Rev. Immunol. 32, 403–432 (2014).

  10. 10.

    Murray, I. A., Patterson, A. D. & Perdew, G. H. Aryl hydrocarbon receptor ligands in cancer: friend and foe. Nat. Rev. Cancer 14, 801–814 (2014).

  11. 11.

    Gandhi, R. et al. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3+ regulatory T cells. Nat. Immunol. 11, 846–853 (2010).

  12. 12.

    Rothhammer, V. et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat. Med. 22, 586–597 (2016).

  13. 13.

    Yamada, T. et al. Constitutive aryl hydrocarbon receptor signaling constrains type I interferon-mediated antiviral innate defense. Nat. Immunol. 17, 687–694 (2016).

  14. 14.

    Quintana, F. J. et al. An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc. Natl Acad. Sci. USA 107, 20768–20773 (2010).

  15. 15.

    Mezrich, J. D. et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 185, 3190–3198 (2010).

  16. 16.

    Opitz, C. A. et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478, 197–203 (2011).

  17. 17.

    Bessede, A. et al. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature 511, 184–190 (2014).

  18. 18.

    Kimura, A. et al. Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses. J. Exp. Med. 206, 2027–2035 (2009).

  19. 19.

    Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y. & Greenleaf, W. J. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat. Methods 10, 1213–1218 (2013).

  20. 20.

    Zhao, B., Degroot, D. E., Hayashi, A., He, G. & Denison, M. S. CH223191 is a ligand-selective antagonist of the Ah (dioxin) receptor. Toxicol. Sci. 117, 393–403 (2010).

  21. 21.

    Nguyen, N. T. et al. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc. Natl Acad. Sci. USA 107, 19961–19966 (2010).

  22. 22.

    Miles, K. et al. A tolerogenic role for Toll-like receptor 9 is revealed by B-cell interaction with DNA complexes expressed on apoptotic cells. Proc. Natl Acad. Sci. USA 109, 887–892 (2012).

  23. 23.

    Guiducci, C. et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465, 937–941 (2010).

  24. 24.

    Barrat, F. J. et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202, 1131–1139 (2005).

  25. 25.

    Legge, K. L. et al. Coupling of peripheral tolerance to endogenous interleukin 10 promotes effective modulation of myelin-activated T cells and ameliorates experimental allergic encephalomyelitis. J. Exp. Med. 191, 2039–2052 (2000).

  26. 26.

    McGaha, T. L., Chen, Y., Ravishankar, B., van Rooijen, N. & Karlsson, M. C. Marginal zone macrophages suppress innate and adaptive immunity to apoptotic cells in the spleen. Blood 117, 5403–5412 (2011).

  27. 27.

    Sharma, M. D. et al. The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment. Sci. Adv. 1, e1500845 (2015).

  28. 28.

    Surh, C. D. & Sprent, J. T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 372, 100–103 (1994).

  29. 29.

    Cohen, J. J. Glucocorticoid-induced apoptosis in the thymus. Semin. Immunol. 4, 363–369 (1992).

  30. 30.

    McGaha, T. L., Sorrentino, B. & Ravetch, J. V. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 307, 590–593 (2005).

  31. 31.

    Lamas, B. et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat. Med. 22, 598–605 (2016).

  32. 32.

    Bjeldanes, L. F., Kim, J. Y., Grose, K. R., Bartholomew, J. C. & Bradfield, C. A. Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3-carbinol in vitro and in vivo: comparisons with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Proc. Natl Acad. Sci. USA 88, 9543–9547 (1991).

  33. 33.

    Schiering, C. et al. Feedback control of AHR signalling regulates intestinal immunity. Nature 542, 242–245 (2017).

  34. 34.

    Bradlow, H. L. & Zeligs, M. A. Diindolylmethane (DIM) spontaneously forms from indole-3-carbinol (I3C) during cell culture experiments. In Vivo 24, 387–391 (2010).

  35. 35.

    Nguyen, L. P. & Bradfield, C. A. The search for endogenous activators of the aryl hydrocarbon receptor. Chem. Res. Toxicol. 21, 102–116 (2008).

  36. 36.

    Dieker, J. et al. Circulating apoptotic microparticles in systemic lupus erythematosus patients drive the activation of dendritic cell subsets and prime neutrophils for NETosis. Arthritis Rheumatol. 68, 462–472 (2016).

  37. 37.

    Beischlag, T. V., Luis Morales, J., Hollingshead, B. D. & Perdew, G. H. The aryl hydrocarbon receptor complex and the control of gene expression. Crit. Rev. Eukaryot. Gene Expr. 18, 207–250 (2008).

  38. 38.

    Christensen, S. R. et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25, 417–428 (2006).

  39. 39.

    Sisirak, V. et al. Digestion of chromatin in apoptotic cell microparticles prevents autoimmunity. Cell 166, 88–101 (2016).

  40. 40.

    Grönwall, C., Vas, J. & Silverman, G. J. Protective roles of natural IgM antibodies. Front. Immunol. 3, 66 (2012).

  41. 41.

    Flaveny, C. A. & Perdew, G. H. Transgenic humanized AHR mouse reveals differences between human and mouse AHR ligand selectivity. Mol. Cell. Pharmacol. 1, 119–123 (2009).

  42. 42.

    Flaveny, C. A., Murray, I. A., Chiaro, C. R. & Perdew, G. H. Ligand selectivity and gene regulation by the human aryl hydrocarbon receptor in transgenic mice. Mol. Pharmacol. 75, 1412–1420 (2009).

  43. 43.

    Hochberg, M. C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40, 1725 (1997).

  44. 44.

    Gladman, D. D., Ibañez, D. & Urowitz, M. B. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 29, 288–291 (2002).

  45. 45.

    Helft, J. et al. GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c+MHCII+ macrophages and dendritic cells. Immunity 42, 1197–1211 (2015).

  46. 46.

    Shinde, R. et al. B cell-intrinsic IDO1 regulates humoral immunity to T cell-independent antigens. J. Immunol. 195, 2374–2382 (2015).

  47. 47.

    Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, (15–21 (2013).

  48. 48.

    Yates, A. et al. Ensembl 2016. Nucleic Acids Res. 44(D1), D710–D716 (2016).

  49. 49.

    Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).

  50. 50.

    Bacsi, S. G., Reisz-Porszasz, S. & Hankinson, O. Orientation of the heterodimeric aryl hydrocarbon (dioxin) receptor complex on its asymmetric DNA recognition sequence. Mol. Pharmacol. 47, 432–438 (1995).

  51. 51.

    Mascanfroni, I. D. et al. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α. Nat. Med. 21, 638–646 (2015).

  52. 52.

    Qazi, K. R., Gehrmann, U., Domange Jordö, E., Karlsson, M. C. & Gabrielsson, S. Antigen-loaded exosomes alone induce Th1-type memory through a B-cell-dependent mechanism. Blood 113, 2673–2683 (2009).

Download references


We thank F. Barrat (Weill Cornell College of Medicine) for the TLR inhibitor and control oligonucleotides; M. Shlomchik, A. Marinov and Z. Rahman for assistance with the analysis of SLE-prone mice; N. Winegarden and the Princess Margaret Genomics Centre for assistance with sequence analysis; K. Hultenby and B. Calvieri for performing electron microscopy; J.C. Zuniga-Pflucker for advice during development of the research report; M. Butler for assistance with the acquisition of PBMCs from healthy control subjects; and P. Ohashi and D. Brooks for reading and critiquing the manuscript. Supported by the US National Institutes of Health (AI105500, AR067763 and CA190449), the Medicine by Design/Canada First Research Excellence Fund (T.L.M.), the Swedish Medical Research Council and the Karolinska Institute (S.G.).

Author information


  1. Tumor Immunotherapy Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

    • Rahul Shinde
    • , Kebria Hezaveh
    • , Marie Jo Halaby
    • , Tiago da Silva Medina
    • , Reema Deol
    • , Sara Lamorte
    • , Drew Wallace
    • , Daniel D. De Carvalho
    •  & Tracy L. McGaha
  2. Department of Immunology, University of Toronto, Toronto, ON, Canada

    • Rahul Shinde
    • , Kebria Hezaveh
    • , Marie Jo Halaby
    • , Kieran P. Manion
    • , Yuriy Baglaenko
    • , Sara Lamorte
    • , Joan Wither
    •  & Tracy L. McGaha
  3. Department of Pathology, New York University School of Medicine, New York, NY, USA

    • Andreas Kloetgen
    •  & Aristotelis Tsirigos
  4. Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada

    • Ankur Chakravarthy
    •  & Daniel D. De Carvalho
  5. Krembil Research Institute, University Health Network, Toronto, ON, Canada

    • Kieran P. Manion
    • , Yuriy Baglaenko
    •  & Joan Wither
  6. Department of Medicine, Unit for Immunology and Allergy, Karolinska Institute, Stockholm, Sweden

    • Maria Eldh
    •  & Susanne Gabrielsson
  7. Department of Immunology, Pennsylvania State University School of Medicine, Hershey, PA, USA

    • Sathi Babu Chodisetti
  8. Department of Cancer Immunology, Genentech, San Francisco, CA, USA

    • Buvana Ravishankar
  9. Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    • Haiyun Liu
  10. Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA

    • Kapil Chaudhary
  11. Department of Paediatrics, Medical College of Georgia, Augusta, GA, USA

    • David H. Munn
  12. Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY, USA

    • Aristotelis Tsirigos
  13. Applied Bioinformatics Laboratories, New York University School of Medicine, New York, NY, USA

    • Aristotelis Tsirigos
  14. Department of Medicine, Medical College of Georgia, Augusta, GA, USA

    • Michael Madaio
  15. University of Toronto Lupus Clinic, University of Toronto, Toronto, ON, Canada

    • Zahi Touma
  16. Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada

    • Zahi Touma
  17. Department of Medicine, University of Toronto, Toronto, ON, Canada

    • Zahi Touma
    •  & Joan Wither


  1. Search for Rahul Shinde in:

  2. Search for Kebria Hezaveh in:

  3. Search for Marie Jo Halaby in:

  4. Search for Andreas Kloetgen in:

  5. Search for Ankur Chakravarthy in:

  6. Search for Tiago da Silva Medina in:

  7. Search for Reema Deol in:

  8. Search for Kieran P. Manion in:

  9. Search for Yuriy Baglaenko in:

  10. Search for Maria Eldh in:

  11. Search for Sara Lamorte in:

  12. Search for Drew Wallace in:

  13. Search for Sathi Babu Chodisetti in:

  14. Search for Buvana Ravishankar in:

  15. Search for Haiyun Liu in:

  16. Search for Kapil Chaudhary in:

  17. Search for David H. Munn in:

  18. Search for Aristotelis Tsirigos in:

  19. Search for Michael Madaio in:

  20. Search for Susanne Gabrielsson in:

  21. Search for Zahi Touma in:

  22. Search for Joan Wither in:

  23. Search for Daniel D. De Carvalho in:

  24. Search for Tracy L. McGaha in:


R.S., K.H., R.D., M.E., S.L., D.W. and S.G. executed the biochemical, cell biological and in vitro experiments; R.S., M.J.H., B.R., H.L. and K.C. performed the animal experiments; A.K. and A.T. analyzed the RNA-seq results; R.S., A.C., T.d.S.M. and D.D.D.C. performed the ATAC-seq experiments and analysis; M.M. assigned scores for renal pathology; K.P.M., Y.B., M.M., S.B.C., D.H.M., S.G., Z.T. and J.W., contributed reagents and human samples and to discussions; R.S., K.H., M.J.H., A.K., A.C. and T.L.M. prepared figures; R.S. and T.L.M. wrote the paper; and T.L.M. designed and supervised the research.

Competing interests

The authors declare no competing interests.

Corresponding author

Correspondence to Tracy L. McGaha.

Integrated supplementary information

  1. Supplementary Figure 1 Apoptotic cell activation of AhR is contact and phagocytosis dependent.

    (a) BMDC of the indicated genotype were co-cultured with B6 apoptotic thymocytes (Ap-BMDC) for 8h and indicated mRNA species were measured by sqPCR. (b) BMDM were cultured with apoptotic cells in a trans-well or in direct contact (Ap-BMDM) and measured at the indicated time points for Cyp1a1 expression by sqPCR. (c) Ap-BMDM were cultured with 1μM cycloheximide (CHX) and Cyp1a1 mRNA was measured by sqPCR. (d) BMDM were cultured with apoptotic or necrotic cells (3x freeze/thawed) as in b and Cyp1a1 mRNA was quantified by sqPCR. (e) BMDM were cultured with live or apoptotic thymocytes and Cyp1a1 mRNA was measured after 6h by sqPCR. Times indicate culture period post-irradiation prior to addition to BMDM culture. (f) Ap-BMDM were co-cultured with CFSE-labeled apoptotic cells for 2h and assessed efferocytosis by flow cytometry. Cytochalsin B was used in the co-culture assay to block phagocytosis. To mask phosphatidylserine, apoptotic cells were incubated with purified Annexin V at 50 μg/ml for 10 min prior to co-culture. Pan-caspase inhibitor z-vad(ome)-fmk was used to inhibit apoptosis in thymocytes prior to addition to BMDM cultures. (g) Ap-BMDM described in f were measured for induction of Cyp1a1 mRNA by sqPCR. For a to e,g values were normalized against β-actin. *=P≤ 0.05, **=P≤ 0.01 as determined by two-sided Student’s t-test. For all experiments n=3 biologically independent samples per group. Bars are mean value +/- standard deviation. Experiments were repeated three times with similar results.

  2. Supplementary Figure 2 Diseases and functional pathways predicted by IPA to be differentially regulated after inhibition of AhR signaling.

    IPA analysis demonstrating significantly enriched diseases and functions separated by categories and functions. Bars represent activation z-scores of given process for Ap-BMDM in the presence (shown on left) or absence (shown on right) of the AhR inhibitor CH223191.

  3. Supplementary Figure 3 Apoptotic cell-driven AhR induction is independent of IDO and driven by TLR9.

    (a) mRNA for Ido1 was measured by sqPCR in BMDM and Ap-BMDM. (b) Culture supernatants from BMDM cultures treated as described in a were assessed for IDO enzymatic activity (i.e. increased tryptophan conversion to kynurenine) by HPLC. (c) Cyp1a1 message was measured in BMDM and Ap-BMDM cultures by sqPCR. Groups of Ap-BMDM included B6.Ido1−/− or B6 +/- the IDO-inhibitor D-1-methyl-tryptophan (200μm). (d) Ap-BMDM cultures were done in the presence of oligonucleotide inhibitors of TLR7 (IRS 661), TLR9 (IRS 869), or TLR7/9 (IRS 954) (1μM for all inhibitors). Cyp1a1 expression was measured by sqPCR. For a,b,d,d n=3 biologically independent samples per group. Bars and data points in line graphs are mean values for group +/- standard deviation. *=P≤ 0.05, ns= not significant as determined by two-sided Student’s t-test. For sqPCR samples were normalized against Bactin. (e) Full image for immuno-blots shown in Fig. 1c. (f) Full image for immuno-blots shown in Fig. 3b. (g) Full image for immuno-blots shown in Fig. 3d. All Experiments were repeated three times with similar results.

  4. Supplementary Figure 4 FACS sorting strategy for purification of splenic myeloid cell populations from mice and PBMC myeloid cell populations from SLE patients and healthy controls.

    (a) Mouse splenic macrophages and dendritic cells were sorted on the basis of the markers indicated. For DC sorting we included the marker CD103 which is associated with DC that have significant efferocytosis activity. DC-dendritic cell, pDC- plasmacytoid DC. (b) Strategy for sorting of human myeloid cells from PBMC fractions. Lineage markers used to exclude non-myeloid cells were CD56, CD3, and CD19. cDC- conventional myeloid DC, pDC- plasmacytoid DC. In a separate sort CD3, CD4, and CD8 were used to enrich for CD4+ and CD8+ T cells.

  5. Supplementary Figure 5 AhR does not impact dexamethasone-induced thymic involution and Cyp1a1 expression is independent of Ido1 and the microbiome in myeloid cells from lupus prone mice.

    (a) Thymic cell numbers were quantified in B6 mice, B6 mice treated with AhR inhibitor (CH223191), and LysM-AhR cKO mice 24h after dexamethasone administration (0.2 mg per mouse, i/p). Bar graph represents total thymic cell count. (b, c) DC and macrophages were FACS-sorted from the spleen of female, 12 week old mice of the mouse strain indicated on the basis of F4/80, CD11c, CD8α. Expression of mRNA for Cyp1a1 and Ido1 were measured by sqPCR. For a, b, c n=4 biologically independent samples per group. Bars represent the mean +/- the standard deviation. (d) 12 week old female R2B mice were kept on antibiotic water for two weeks. DC and macrophages were sorted as in b and mRNA for Cyp1a1 and Ido1 were measured. Bars represent the value of pooled samples from four mice. For all sqPCR analysis samples were normalized against Bactin. ***=P<0.001 as determined by two-sided Student’s t-test. All experiments were repeated two times with similar results.

  6. Supplementary Figure 6 AhR limits autoimmunity in lupus prone mice.

    (a,b) 8w-old R2B mice were treated with ITE and CH223191. After 8w of treatment splenocytes were assessed by cytometry analysis. (a) Cytometry plots gated on B220+ B cells measuring CD24. (b) Flow cytometry analysis of CD4+CD44high and CD8+CD44high T cell percentages. (c) 8w female R2B mice treated with ITE (AhR agonist), CH223191 (AhR antagonist), or vehicle for 4m. B6 mice were age/sex matched and treated with vehicle. IgG antinuclear antibody (ANA) reactivity was measured. Scale bar=50μm. (d) Immunoglobulin auto-reactivity against dsDNA and histones from the mice in c was measured by ELISA. (e) Kidneys were collected from mice in c, 5μm sections were stained with H&E and pathology of glomeruli and tubules was scored in a blinded manner. Scale bar=100μm. For all experiments n=5 biologically independent samples per group. For all graphs bars are mean values +/- standard deviation. *=P≤ 0.05, **=P≤ 0.01 and ns= not significant as determined by two-sided Student’s t-test. Experiments were repeated three times with similar results.

  7. Supplementary Figure 7 Apoptotic cells and SLE microparticles drive AhR activation and IL-10 production in human macrophages.

    (a) Irradiated, apoptotic jurkat cells were cultured with PBDM (Ap-PBDM) for 8h. Culture supernatants were collected and IL-10 and IL-6 were measured by ELISA and mRNA was collected for assessment of CYP1A1 (normalized against BACTIN) by sqPCR. (b) Staurosporine treated, apoptotic jurkat cells were treated with DNAse and cultured with PBDM for 8h (Ap-PBDM). Culture supernatants were collected indicated proteins were measured by ELISA and mRNA was collected for assessment of CYP1A1 sqPCR. (c) Serum concentrations of kynurenine (Kyn) and indole-3-propionic acid (IPA) were measured by HPLC from samples described in Supplementary Tables 1,2,3. Bars are mean +/- standard deviation. *=P≤ 0.05, ns= not significant as determined by the Wilcoxon rank-sum test. (d) Microparticles purified from plasma of patient samples described in Supplementary Table 4,5 were quantified by flow cytometry. (e) Representative electron micrographs illustrating morphology and size distribution of microparticles from plasma of SLE patients and controls. Bar is 500nm and magnification is 50,000x. (f) Microparticles were assessed by flow cytometry for surface expression of the markers indicated. MFI ratio represents the relative mean fluorescence intensity (MFI) for the indicated CD marker versus the MFI for isotype controls. (g) Microparticls origin was analyzed by expression of endothelial (CD31), haematopoietic (CD45), neutrophil (CD66b), B cell (CD19), and T cell (CD3) markers. % positive indicates the % of microparticles that were positive for the markers compared to isotype controls. (h) Microparticles isolated from the plasma of SLE patients were added to cultures of healthy donor PBDM (20% volume/volume) +/- AhR antagonist CH223191. Eight hours later, culture supernatants were collected to measure cytokine production by ELISA. For a, b, h n=5 biologically independent samples per group. Bars are mean values +/- standard deviation and *=P≤0.05, **=P≤0.01 as determined by two sided Student’s t-test. All Experiments were repeated three times with similar results.

Supplementary information

  1. Supplementary Figures and Tables

    Supplementary Figures 1-7 and Supplementary Tables 1-8

  2. Reporting Summary